key: cord-0799111-oktbb5wg
authors: Mendoza, E. J.; Warner, B.; Safronetz, D.; Ranadheera, C.
title: Crimean–Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures
date: 2018-04-20
journal: Zoonoses Public Health
DOI: 10.1111/zph.12469
sha: c4c5368083fa3f1294814dc60e25ca76fff8e705
doc_id: 799111
cord_uid: oktbb5wg

Crimean–Congo haemorrhagic fever (CCHF) is a widespread tick‐borne viral zoonosis with a case‐fatality rate ranging from 9% to 50% in humans. Although a licensed vaccine to prevent infection by the CCHF virus (CCHFV) exists, its ability to induce neutralizing antibodies is limited and its efficacy against CCHFV remains undetermined. In addition, controlling CCHF infections by eradication of the tick reservoir has been ineffective, both economically and logistically, and the treatment options for CCHF remain limited. In this review, we first critically discuss the existing animal models to evaluate therapeutics for CCHF. We then review the therapeutic options for CCHF that have been investigated in human cases, followed by investigational drugs that have been evaluated in pre‐clinical studies. We highlight the importance of understanding human prognostic factors in developing an animal model for CCHF that recapitulates hallmarks of human disease and its implication for selecting therapeutic candidates.

Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne disease caused by the CCHF virus (CCHFV). CCHFV was characterized during the Crimean outbreak in 1944 and later that the same agent was the cause of disease in the Congo in 1956 (Casals, 1969) . A member of the Orthonairovirus genus within the Nairoviridae family, CCHFV is primarily transmitted through direct contact of skin or mucous membranes with infectious blood or tissues, by the bite of infected Hyalomma species ticks or contact with viremic livestock (Vorou, Pierroutsakos, & Maltezou, 2007) . Furthermore, fatal nosocomial spread of CCHFV in the hospital setting is very common (Oestereich et al., 2014) . Upon infection, CCHF progresses through four stages of disease: incubation, pre-haemorrhagic, haemorrhagic and convalescence. The duration of the incubation stage is usually 1-3 days when CCHFV is transmitted via tick bite and 5-13 days when transmitted via contact with infected blood or tissues. The pre-haemorrhagic stage follows, with non-specific viral symptoms such as fever, muscle soreness, chills, photophobia, headache and nausea. In non-severe cases, individuals clear the infection and the pre-haemorrhagic stage associated symptoms resolve. In severe cases, the disease progresses to the haemorrhagic stage occurs 3-6 days after infection, with symptoms such as petechiae and haemorrhaging of internal organs, gastrointestinal system, gums and nose (Shayan, Bokaean, Shahrivar, & Chinikar, 2015) . Fatal cases are usually a result of multiple organ failure. The fatality rate of CCHF has ranged from 9% to 50% in past outbreaks (Dilber et al., 2010) .

Those who survive the haemorrhagic stage experience the convalescent phase, which is characterized by memory loss, headache, dizziness, weak pulse, hair loss, anorexia and vision abnormalities (Shayan et al., 2015) . Long-term sequelae, such as neurological problems and impaired vision, have been documented; however, these are rarely permanent (Hoogstraal, 1979) . To date, it is still unclear whether survivors develop immunity to subsequent CCHFV infections, but IgG responses lacking in fatal cases are induced in non-fatal cases in humans (Ergonul, Tuncbilek, Baykam, Celikbas, & Dokuzoguz, 2006) .

Crimean-Congo haemorrhagic fever is a geographically widespread zoonotic disease, ranging from the Middle East and Asia to South Africa and Eastern Europe. However, most documented CCHF cases have been reported in Turkey. CCHFV remains a risk group-4 pathogen for its ability to cause severe to fatal disease in humans and the absence of effective options for pre-or post-exposure prophylaxis.

Under these circumstances, CCHFV is still deemed a possible weapon for bioterrorism (Bronze, Huycke, Machado, Voskuhl, & Greenfield, 2002) . In this review, we explore the past, summarizing historical measures of CCHFV control and prevention. We then review the present state of existing animal models to evaluate therapeutics and interventions tested in human cases of CCHFV infection. Finally, we discuss investigational drugs in pre-clinical studies. This review aimed to highlight the importance of developing an animal model for CCHF that recapitulates hallmarks of human disease in order to optimize preclinical drug testing and thereby improve our chances in developing an effective medical countermeasure for humans.

In multiple instances attempts to control CCHF, the eradication of the CCHFV tick vector has been inefficient, both economically and logistically (Keshtkar-Jahromi et al., 2011) . It remains difficult to control CCHFV by culling domestics animal hosts because reservoirs, such as cattle, goats and sheep, often remain asymptomatic even when highly viremic (Whitehouse, 2004) . As many nosocomial outbreaks of CCHFV have occurred in endemic areas (Burney, Ghafoor, Saleen, Webb, & Casals, 1980; Conger et al., 2015; Naderi, Sheybani, Bojdi, Khosravi, & Mostafavi, 2013; Pshenichnaya & Nenadskaya, 2015; , isolation rooms for CCHF have been established in treatment units throughout Turkey, Iran, Pakistan, Russia, Georgia, Bulgaria, India, Kazakhstan and Kosovo. In addition, adequate training for the use of personal protective equipment and effective waste management and disinfection in the hospital setting have been implemented (Fletcher et al., 2017) . However, as CCHF cases often enter healthcare facilities with non-specific flu-like symptoms, late recognition and diagnosis of CCHF cases may hinder the effectiveness of these measures in reducing the occurrence of hospital-acquired CCHFV infection (Fletcher et al., 2017) .

Another attempt to control CCHFV was the development of an inactivated CCHFV vaccine isolated from the brains of infected rats and mice in the 1970s. The vaccine gained approval from the Soviet Ministry of Health as a preventative measure against CCHF after demonstrating safety and immunogenicity in humans. Although this vaccine elicited robust T-cell responses against CCHFV and high antibody levels upon initial vaccination, four doses were required to induce even low levels of CCHFV-neutralizing antibodies (Mousavi-Jazi, Karlberg, Papa, Christova, & Mirazimi, 2012) . To date, the protective efficacy of this vaccine in humans has not been established in controlled clinical trials and the crude nature of vaccine preparation makes it a less likely candidate for widespread use (Buttigieg et al., 2014) . In addition, as the correlates of protection against CCHFV remain unclear, the development of an efficacious vaccine to prevent the disease remains an obstacle in the field. Thus, in the absence of adequate preventative options, therapeutic intervention is the primary mode of preventing mortality from CCHF, although their efficacy remains elusive.

The evaluation of therapeutic candidates for CCHF has been hindered due to the historical lack of an animal model that recapitulates hallmarks of CCHF in humans. Many animal models that have been evaluated thus far develop viremia upon infection, but do not develop any clinical features of disease (Table 1) . Other than humans, the only mammals that develop disease upon CCHFV infection are those lacking a fully functional immune system, including neo-natal mice (Smirnova, 1979) , signal transducer and activator of transcription 1 (STAT-1) knockout mice (Bente et al., 2010) and interferon α/β receptor (IFNAR−/−) knockout mice (Oestereich et al., 2014) . Thus, these are currently the most extensively used animal models for the pre-clinical evaluation of interventions against CCHFV.

• Crimean-Congo haemorrhagic fever (CCHF) is a public health concern, ranging from the Middle East and Asia (Smirnova, 1979) Non-lethal (Smirnova, 1979) • Increased viremia • Anti-CCHFV antibodies (Smirnova, 1979) Disadvantages:

• Non-lethal • No clinical signs of disease Newborn animals: White rats Cotton rats Various CCHFV isolates and doses (i.c or i.p.)

Varied time to death (Smirnova, 1979) • Increased viremia (Smirnova, 1979) Advantages:

• Lethal models • Cost-effective Disadvantages:

• Immature immune system prevents evaluation of vaccines Neonatal mice 10 3.5 PFU CCHFV IbAr 10200 (i.c or i.p.) (Logan et al., 1989) 4-6 days post-infection (i.p.) (Logan et al., 1989) • Increased viremia • Lesions (Logan et al., 1989) Advantages:

• 

The earliest experimental systems in the 1970s that were able to induce lethality utilized either newborn mice, rats, or young mice infected intracranially or intraperitoneally (Salehi, Salehi, Adibi, & Salehi, 2013) . Newborn mice were found to be the most sensitive of this group and were the commonly used animal model for the study of CCHF disease until only recently. The newborn mouse model of CCHFV has been used to study disease pathogenesis, efficacy of treatments and transmission dynamics of the virus via ticks (Logan, Linthicum, Bailey, Watts, & Moulton, 1989; Smirnova, Zubri, Savinov, & Chumakov, 1973; Tignor & Hanham, 1993) . The early use of newborn mice for studying CCHFV was necessary due to the lack of disease seen in infection of adult animals of several species, in which viremia could be detected, but show no apparent signs of disease before clearing the virus (Smirnova, 1979) .

However widely used early on, newborn animal models are typically not representative of disease progression in adult animals or in humans and newborns are often susceptible to a wide range of pathogens that do not cause overt disease in mature animals.

Interestingly, several larger animals have been experimentally infected with CCHFV such as sheep, cattle, donkeys and ostriches to study the persistence of the virus in these species, rather than to model human disease (Smirnova, 1979; Swanepoel et al., 1998) .

Since the advent of genetic engineering techniques, the use of knockout mice has proven to be a more suitable model for the study of CCHFV pathogenesis and pre-clinical testing of CCHFV vaccines and therapeutics.

STAT-1 and IFNAR−/− knockout mice have both recently been used as lethal models of CCHF disease (Bente et al., 2010; Bereczky et al., 2010; Zivcec et al., 2013) . These animal models are defective in the innate immune response, which is believed to be critical in protecting mice from productive infection with CCHFV. STAT-1 deficiency prevents the upregulation of genes due to a signal by either type I or type II interferons. These knockout mice succumb to infection within 3-5 days and suffer from fever, leukopenia, thrombocytopenia and elevated liver enzymes (Bente et al., 2010) .

STAT-1 knockout mice also have high levels of viremia in the liver and spleen along with elevated pro-inflammatory cytokine production. In contrast, the genetic defect of IFNAR−/− mice specifically affects the interferon type I signalling. IFNAR−/− mice infected with CCHFV develop acute disease and succumb to infection within 5 days (Bereczky et al., 2010; Zivcec et al., 2013) . High viral loads are seen in the spleen, liver, kidneys, heart, lungs, lymph nodes and blood of the mice (Bereczky et al., 2010; Zivcec et al., 2013) .

Additionally, there is significant enlargement of the liver in infected IFNAR−/− mice. An advantage to using these mouse models is that Advantages:

• Bereczky et al., 2010; Swanepoel et al., 1989; Zivcec et al., 2013) . Both models are useful in studying the pathogenesis of disease as well as testing treatment options. They can also provide insights into immunological mechanisms of disease and viral clearance. Although using immunocompromised mice for the testing of vaccines is not ideal, these models are also a suitable model to test vaccines, providing an option that was not available with the use of newborn animals.

An interesting advance in animal models that could potentially serve as a model for CCHF disease is humanized mice. In contrast to previous mouse models of CCHFV infection, these mice develop functional human immune systems, including production of T and B cells following the engraftment of hematopoietic stem cells, PBMCs or foetal liver and thymus (Brehm, Shultz, & Greiner, 2010) . , 1985) . While some of these treatments demonstrate some therapeutic benefit in humans, no statistical significance has been established thus far.

Supportive 

is a small-molecule drug that has been implicated for the treatment of infections caused by a variety of DNA and RNA virus infections, such as respiratory syncytial virus and hepatitis C virus (Dusheiko et al., 1996; Hall et al., 1983) . It has also demonstrated efficacy in the treatment of haemorrhagic fever caused by Lassa virus infection (McCormick et al., 1986) . Synthesized in the 1970s, ribavirin is a purine nucleoside analogue, which can directly inhibit viral transcription by binding viral polymerases or by incorporation into nascent RNA genomes, causing viral RNA mutagenesis.

It can also directly inhibit translation by inhibiting viral capping enzymes (Tam, Lau, & Hong, 2001) . Ribavirin can also indirectly mediate antiviral activities via immunomodulatory effects, by inducing antiviral type 1 cytokines (IFNγ, TNFα, IL-2) and suppressing pro-viral cytokines (IL-4, IL-10) (Tam et al., 2001) . Lastly, it inhibits host inosine monophosphate dehydrogenase, disrupting intracellular GTP concentration needed for viral replication (Tam et al., 2001) . CCHFV is sensitive to ribavirin in a strain-dependent manner in vitro (Watts, Ussery, Nash, & Peters, 1989) . CCHFV strains IbAr 10200 (Nigeria), SPU 128/81(South Africa) and HY-13(China) were highly sensitive to ribavirin, with 50% effective inhibitory doses (ED50) between 4-6 μg/ml; CCHFV strains UG 3011 (Uganda), AP-92 (Greece) and SPU 41/84 (South Africa) were less sensitive to ribavirin, with ED50s between 9 and 16 μg/ml .

Control and Prevention promote the use of ribavirin for the treatment of CCHF, efficacy of ribavirin in human CCHF cases remains controversial. In favour of ribavirin as a CCHF therapeutic, the efficacy of oral ribavirin in suspected and confirmed CCHF patients was 34% and 80% in a study conducted in Iran, respectively (Mardani, Jahromi, Naieni, & Zeinali, 2003) . Eight CCHF patients all survived severe disease when administered oral ribavirin within a mean of 5.5 days (Ergönül et al., 2004) . A multivariate analysis of confirmed CCHF patients at a Turkish hospital demonstrated that those treated with oral ribavirin and admitted within 2 days of symptom onset were at decreased risk of experiencing severe disease (Ozbey, Kader, Erbay, & Ergönül, 2014) . In a similar multivariate analysis of CCHF patients stratified by disease severity at another site in Turkey, ribavirin was found to be effective in reducing the case-fatality rate among moderately ill patients (Dokuzoguz et al., 2013) .

In contrast, most current studies support the conclusion that ribavirin is not effective in the treatment of CCHF. A meta-analysis conducted on one randomized controlled trial and seven observational studies demonstrated that ribavirin did not improve survival in CCHF patients and was unable to provide significant clinical benefit (Ascioglu, Leblebicioglu, Vahaboglu, & Chan, 2011) . In other studies, oral ribavirin treatment of CCHF patients did not confer significant benefit regarding viral load or disease progression compared to patients who did not receive ribavirin, nor did it improve survival rates (Bodur et al., 2011; Ceylan, Calıca, Ak, Akkoyunlu, & Turhan, 2013; Elaldi et al., 2009) . Additionally, patients given ribavirin experienced delayed return to normal leucocyte counts and longer hospitalization times. However, these findings were not statistically significant . The discrepancies surrounding the efficacy of 

Methylprednisolone is a synthetic corticosteroid that has been licensed for the treatment of inflammatory ailments such as arthritis and bronchitis, as well as autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis (Sloka & Stefanelli, 2005) . Methylprednisolone binds intracellular glucocorticoid receptors, which activates the expression of genes that modulate the immune system and aid in the restoration of blood barrier disruption. The anti-inflammatory effects of methylprednisolone are believed to be of benefit in cases where disease pathogenesis is mediated by deleterious host immune responses (Tam et al., 2012) .

Methylprednisolone has been evaluated in human trials for viral ailments, such as coronavirus-associated severe acute respiratory syndrome (SARS) and dengue virus. However, these studies failed to establish statistically significant efficacy of corticosteroid treatment in patients (Auyeung et al., 2005; Ho et al., 2003; Tam et al., 2012) . 

Convalescent blood products harvested from recovered patients aims to provide pathogen-specific antibodies generated during disease progression to newly infected patients and has been successful for the treatment of diseases such as measles, whooping cough, typhoid fever, scarlet fever and mumps (Berger, 2002; Dewar, 1946; McGuinness, Stokes, & Mudd, 1937; Stoll, 1919) . Although the ef- for up to 4 days following symptom onset did not exhibit statistically improved outcomes over non-treated patients (Leshchinskaya & Martinenko, 1970) . A patient administered 300 mL of convalescent serum during a nosocomial outbreak of CCHF in Dubai survived illness and experienced a shorter convalescent period compared to other survivors (Suleiman et al., 1980 , 1985) . Furthermore, these findings would suggest administration of protective antibodies may be a successful direction to explore.

Prognostic factors that predict mortality in CCHFV cases continues to be of crucial importance in the field. In the medical setting, the ability to predict the clinical course of disease allows physicians to make crucial decisions about disease management, such as whether a patient could be managed at a local hospital or if they should be transported to medical centres with greater intensive care capacities . Identifying the factors more strongly associated with fatality may allow for the optimization of animal models, which should ideally exhibit similar clinical signs and laboratory findings as humans. The selection of therapeutic agents that specifically address these signs and biomarkers may then show more benefit in preventing mortality in human cases.

Many studies have attempted to understand clinical signs associated with mortality in humans by comparing those seen in fatal and nonfatal CCHF cases Ergonul, Celikbas, Baykam, Eren, & Dokuzoguz, 2006; Ozturk et al., 2012) . Early in the disease course, CCHF patients present with fever and loss of appetite, however, these are not significantly associated with mortality. Bleeding is a key feature of the subsequent haemorrhagic stage of CCHFV infection (Cevik et al., 2008) . As depicted in Table 2 ., hematemesis (blood in vomit), epistaxis (bloody nose), gingival bleeding and melena (blood in stool), have been shown in multiple studies to be significantly associated with death (Cevik et al., 2008; Ergonul, Tuncbilek et al., 2006; Kaya et al., 2014; Ozturk et al., 2012) . Bleeding from the skin was a significant prognostic factor in the study by Ozturk et al. (2012) . In addition, an overall consensus between these studies shows that somnolence is another clinical sign significantly associated with mortality. While petechiae, maculopapular rash, hepatomegaly, splenomegaly, eccymosis and jaundice are often seen in CCHF patients, they are currently not significant sign of mortality.

To date, neonatal mice, IFNAR−/− mice, STAT-1 knockout mice and Hu-NSG™-SGM3 mice have been unable to demonstrate any of these clinical signs upon CCHFV infection. However, IFNAR−/− mice, STAT-1 knockout mice and Hu-NSG™-SGM3 mice demonstrate loss of appetite and show CCHFV antigen in the liver and spleen (Bente et al., 2010; Spengler et al., 2017; Zivcec et al., 2013) .

Abnormal blood clotting as a result of thrombocytopenia has been established as a mortality factor in CCHF cases . In a study comparing coagulopathy markers of fatal CCHF cases (n = 59) with non-fatal patients (n = 74), significant prognostic factors associated with mortality were identified. 

Many studies have demonstrated that abnormal leucocyte counts and elevated liver enzymes are hallmarks of CCHFV infection and can be used to predict fatal outcome in patients . In a retrospective study comprising CCHFV patients confirmed by PCR or anti-CCHFV IgM antibodies, the leucocyte, lymphocyte, neutrophil and monocyte levels were compared between fatal (n = 36) and non-fatal (n = 184) cases. Using Receiving

Operating Curve analysis, significant risk factors for mortality established in this study were increased neutrophil levels (p = .01) and decreased lymphocyte (p = .037) and monocyte (p = .001) levels. Independent predictors of mortality were leucocytes >2,950 per μl, lactate dehydrogenase >967.5 U/L and alanine aminotransferase >119.5 U/L, which increased mortality risk by 7-to 12-fold (Bastug et al., 2016) . This study suggests the importance CCHFV (Ozturk et al., 2012) . It is still unknown whether virus neutralization or other antibody-mediated mechanisms are correlated with protection.

Both the IFNAR−/− and STAT-1 knockout mouse models have demonstrated leukopenia when infected with CCHFV (Bente et al., 2010; Zivcec et al., 2013) . These factors have yet to be examined in the Hu-NSG™-SGM3 mouse model (Spengler et al., 2017) .

In another comparison between fatal (n = 11) and non-fatal (n = 20)

cases of CCHFV, increased IL-6 (326.1 ± 74.9 vs. 70.7 ± 17.4 pg/mL; p < .001) and TNFα (161.3 ± 26.3 vs. 77.3 ± 7.2 pg/mL; p < .001)

were identified as significant markers of mortality. IL-10 levels were decreased in fatal cases compared to survivors, but not to a statistically significant level. IFNγ was similar between both groups (Kaya et al., 2014) . A more recent student study similarly showed increased IL-6 and TNFα in fatal cases (n = 5) compared with non-fatal cases (n = 22), with IL-8 being an additional marker for fatality (Ergönül et al., 2017) . 

As mentioned previously, the CCHF therapeutics which have been However, as ribavirin and methylprednisolone are clinically approved drugs that have undergone phase I safety testing in humans and in the absence of any therapeutic with proven benefit for CCHFV, ribavirin was repurposed and evaluated in phase II or III efficacy trials. However, the lack of significant benefit conferred by ribavirin for CCHF patients in these trials may have been a predictable outcome. TA B L E 3 Therapeutic options for the treatment of Crimean-Congo haemorrhagic fever Ribavirin Inhibits viral replication and indirectly modulates host immune response (Tam et al., 2001) Inhibits CCHFV replication in Vero E6 cell line (Oestereich et al., 2014) IFNAR−/− mice (100 FFU CCHFV): Protected 1/7 (14%) when administered on 0 dpi (Oestereich et al., 2014 ) STAT-1 knockout mice (10 PFU CCHFV): Protected 6/6 (100%) when daily regimen was initiated 1 hr postinfection or 1 dpi (Bente et al., 2010) . STAT-1 knockout mice (1,000 PFU CCHFV): Protected 60% when given 1 hr postinfection and 0% at 1 dpi (Bente et al., 2010) Pro-ribavirin: Improvement in survival and disease severity (Dokuzoguz et al., 2013; Mardani et al., 2003; Ozbey et al., 2014) . Anti-ribavirin: No statistically significant improvement in outcome for CCHF patients treated with ribavirin (Ascioglu et al., 2011; Bodur et al., 2011; Ceylan et al., 2013; Elaldi et al., 2009; Koksal et al., 2010) Methylprednisolone Modulates host immune response (Tam et al., 2012) Not available No animal data available 5/5 (100%) CCHF patients survived when administered doses 20-30 mg per kg/day intravenously for 5 days, after administration of IVIG and/or G-CSF (Dilber et al., 2010) Convalescent blood products Antibody-mediated effects (neutralization, antibodydependent cell cytotoxicity)

No animal data available 1 patient treated with convalescent serum survived disease (Suleiman et al., 1980) . 5/9 (56%) patients treated with hyperimmune serum survived disease Monoclonal antibodies Antibody-mediated effects (neutralization, antibodydependent cell cytotoxicity)

Anti-Gc mAbs neutralized CCHFV infection of SW-13 cells Anti-Gn mAbs demonstrated less neutralizing activity against CCHFV in SW-13 cells (Bertolotti-Ciarlet et al., 2005) Neonatal mice: 8A1 (Anti-Gc): 100% protection when administered 1 day before infection, 20% when administered 1 dpi 11E7 (Anti-Gc): ~75% protection when administered 1 day before or after infection 6B12 (Anti-Gn): 100% protection when administered 1 day before infection, ~95% protection when administered 1 dpi 10E11 (Anti-Gn): 95% protection when administered 1 day before infection, 90% protection when administered 1 dpi (Bertolotti-Ciarlet et al., 2005) Not tested in human CCHF cases Favipiravir (T-705) Inhibits viral RNA polymerase (Janeba, 2015; Li, Chan, & Lee, 2015; Salata et al., 2015) Inhibits CCHFV replication in Vero E6 cell line (Oestereich et al., 2014) IFNAR−/− mice (100 FFU CCHFV): Protected 5/5 (100%) when treatment initiated up to 2 dpi (Oestereich et al., 2014) Not tested in human CCHF cases (Continues) demonstrated a lack of effectiveness in patients (Dunning et al., 2016; Gupta-Wright, Lavers, & Irvine, 2015) . From these observations, it has been suggested that a lack of prior efficacy testing in current animal models for infection may contribute a drug's lack of benefit in clinical trials (Mendoza, Qiu, & Kobinger, 2016) . Thus, future CCHFV drug candidates are more commonly undergoing pre-clinical testing in the available animal models for CCHFV, which may allow for better prediction of effectiveness when tested in human patients (Table 3) .

Although ribavirin has been evaluated in human cases of CCHFV, it has not been evaluated in any animal model for CCHF until recently. In a study using the IFNAR−/− mouse model for CCHF, ribavirin did not demonstrate statistically significant efficacy against the Afg09-2990 strain of CCHFV in infected IFNAR−/− mice when administered on 0 dpi (1/7; 14%) (Oestereich et al., 2014) . In contrast, ribavirin was able to protect STAT-1 knockout mice from 10 PFU CCHFV challenge when a daily treatment was initiated 1 hr postinfection (6/6; 100%) and 24 hr post-infection (6/6; 100%) (Bente et al., 2010) . However, when challenged with 1,000 PFU CCHFV, only 60% of animals survived when treatment was initiated 1 hr post-infection and no animals survived when treatment was initiated 24 hr post-infection (Bente et al., 2010) .

Monoclonal antibodies (mAbs) targeted to the Gn and/or Gc surface glycoproteins of CCHFV originally developed to identify CCHFV in 1987 are currently being investigated as a treatment for CCHF (Blackburn, Besselaar, Shepherd, & Swanepoel, 1987) . In vitro, Gc-specific, but not Gn-specific mAbs were able to neutralize CCHFV infection of SW-13 cells (Bertolotti-Ciarlet et al., 2005) . Up to 100% protection was achieved when suckling mice were administered anti-Gc mAbs 24 hr prior to lethal CCHFV challenge; however, only up to 70% protection was achieved when administered 24 hr post-CCHFV infection. In contrast, up to 90% protection was achieved when anti-Gn mAbs were administered 24 hr post-infection, suggesting that other mechanisms, such as antibody-dependent cell cytotoxicity or complement-mediated cell lysis, may play a role in protection against CCHFV (Bertolotti-Ciarlet et al., 2005) . It would be of interest to assess the efficacy of these and other antibody-based therapeutics in a model that better recapitulates the human disease such as IFNAR−/− and STAT 1 KO mice.

Arbidol is a broad-spectrum antiviral, which interrupts clathrindependent trafficking, thereby inhibiting viral entry (Blaising et al., 2013) . Arbidol has been used to treat influenza virus in humans and elicits inhibition of virus entry and replication for viruses, such as hepatitis C virus in vitro (Pécheur et al., 2016) . Favipiravir (T-705; 6fluoro-3-hydroxy-2-pyrazinecarboxamide) is a broad-spectrum selective inhibitor of viral RNA polymerase, which has demonstrated efficacy against influenza virus infections in humans (Furuta et al., 2013) . In a study by Oestereich et al. (2014) , both arbidol and T-705 

Arbidol Inhibits viral entry (Blaising et al., 2013) Inhibits CCHFV replication in Vero E6 cell line (Oestereich et al., 2014) IFNAR−/− mice (1,000 FFU CCHFV): Protected 0/5 (0%) when administered 1 day before infection (Oestereich et al., 2014) IFNAR−/− mice (10 FFU CCHFV): Protected 1/5 (20%) when administered 1 day before infection (Oestereich et al., 2014) Not tested in human CCHF cases Chloroquine Inhibits uncoating and post-translational modifications, modulates host immune response (Savarino et al., 2003) Inhibits CCHFV replication in Vero and Huh7 cell lines (Ferraris et al., 2015) No animal data available Not tested in human CCHF cases Chlorpromazine Inhibits formation of clathrin-coated pits, preventing clathrinmediated endocytosis and viral uncoating (Wang et al., 1993) Inhibits CCHFV in Vero and Huh7 cell lines (Ferraris et al., 2015) No animal data available Not tested in human CCHF cases TA B L E 3 (Continued)

Chloroquine is a broad-spectrum antiviral, which inhibits pH-dependent steps of viral replication, including uncoating and post-translational modifications, likely by increasing pH of the endosome, lysosome and Golgi vesicle. In addition, chloroquine elicits immunomodulatory effects, such as inhibiting the production and/or release of interleukin-6 and tumour necrosis factor α (Savarino, Boelaert, Cassone, Majori, & Cauda, 2003) . Chloroquine has been used to treat malaria and has been shown to inhibit the replication of influenza virus, chikungunya virus and dengue virus in cell culture (Farias, Machado, de Almeida Junior, de Aquino, & da Fonseca, 2014; Khan, Santhosh, Tiwari, Lakshmana Rao, & Parida, 2010; Ooi, Chew, Loh, & Chua, 2006) .

Chlorpromazine is a licensed anti-psychotic drug used for the treatment of bipolar disorder and schizophrenia (Gajwani et al., 2006; Leucht, Kitzmantel, Chua, Kane, & Leucht, 2008) . Chlorpromazine has also demonstrated antiviral activity against adenovirus infection in Syrian hamsters (Diaconu et al., 2010) . It has also inhibited Middle

East respiratory syndrome coronavirus (MERS-CoV) and Ebola virus in cell culture (Bhattacharyya et al., 2010; De Wilde et al., 2014) .

Antiviral activity of chlorpromazine is likely mediated by interference of clathrin-coated pits, which prevents clathrin-mediated endocytosis and viral uncoating (Wang, Rothberg, & Anderson, 1993) . Both chloroquine and chlorpromazine were able to inhibit CCHFV infection of Vero and Huh7 cell lines when added up to 6 hr post-infection and up to 24 hr (Ferraris et al., 2015) . Next steps, would involve evaluating these drugs in animal models for CCHFV infection.

The development of lethal animal models of CCHFV infection has allowed for the evaluation of newly developed vaccine candidates to protect against CCHFV. While some vaccines platforms have demonstrated protective efficacy in small animal models, our understanding of correlates of protection against CCHFV infection in humans remains incomplete (Buttigieg et al., 2014; Dowall, Carroll, & Hewson, 2017) . Characterizing the specific immune responses optimal for protection against CCHFV infection in humans will be crucial for future vaccine development.

A Drosophila insect cell-based expression system was used to develop a subunit vaccine comprising the ectodomains of the structural CCHFV glycoproteins Gn and Gc (Kortekaas et al., 2015) . The vaccine induced CCHFV-neutralizing antibodies in STAT-1 knockout mice when administered in a prime-boost regimen. However, the vaccine was unable to offer protection in the STAT-1 knockout mouse model for CCHFV infection when lethally challenged intraperitoneally with the IbAr10200 strain 42 days post-vaccination (Kortekaas et al., 2015) . While the results of this study suggest that CCHFV-neutralizing antibodies may not correlate with protection, future studies should evaluate the role of virus neutralization in other animal models for CCHFV infection to determine whether this is a model-specific phenomenon or a feature that mimics the human response to infection. the IbAr10200 strain 28 days post-prime vaccination (Buttigieg et al., 2014) . Further studies showed that protection conferred by the MVA-GP vaccine in IFNAR−/− mice required both cellular and humoral responses (Dowall et al., 2016) . Future research should evaluate if either or both of these responses are required for protection against CCHFV in human cases. (Garrison et al., 2017) . The study found no direct correlation between the anti-CCHFV glycoprotein antibody response and survival, suggesting that antibodies targeted to other CCHFV proteins and/or the cellular response may be involved in vaccine-mediated protection (Garrison et al., 2017) . While DNA vaccines are advantageous for their cost-effectiveness, ability to induce robust cytotoxic T-cell responses and enhanced stability at different temperatures, they are limited in terms of immunogenicity, requiring adjuvants and electroporation to induce adequate antibody responses (Clem, 2011; Khan, 2013) .

The potential for widespread geographic distribution and highly lethal outbreaks of disease make CCHF an important emerging infectious disease, and a renewed interest in developing vaccines and therapeutic approaches exists. The biocontainment requirements and the lack of suitable animal models have limited research advances in these areas.

Due to the zoonotic nature of the disease and the lack of approved therapies, raising awareness among those at risk is critical for prevention of CCHF. While several therapeutic approaches have been examined, their efficacy has been variable, and there remains a need for reliable therapeutics. The development and testing of reliable therapeutic options will rely upon advances in an understanding of disease pathogenesis in animal models, which to date have been lacking. Suitable animal models would open doors for potential vaccine and therapeutic research that has not been achieved so far. Neonatal and immunodeficient animals have limitations when assessing the course of disease and in testing potential vaccine platforms, but there is optimism that advances in animal models such as humanized mice will advance our understanding of disease progression, immunological correlates of protection against CCHF, and what approaches might best prevent disease. When evaluating pathogenesis of human viruses in animals, the ideal model should be able to host virus replication, exhibit similar prognostic markers as those seen in human cases and recapitulate hallmarks of human disease.

Advances in transgenic and knockout animal models with these characteristics would optimize pre-clinical development of therapeutic candidates which yield more benefit in human CCHF patients. Immune correlates of protection will also provide valuable information for development of specific therapies such as antibody development or anti-inflammatory mediators such as steroids. While our current understanding of CCHF has been established using limited animal models and clinical data, future directives should be aimed at developing more ideal models of infection for pre-clinical testing of vaccines and therapeutics for CCHF. Future advances in these areas would pave the way for informative research that works towards effective vaccines and medical countermeasures against CCHF.

The authors declare no conflict of interest. The authors do not have any relevant affiliations or financial involvement with any organization or entity with a financial interest in the subject matter of the manuscript.

O RCI D C. Ranadheera http://orcid.org/0000-0002-5674-7061

Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever

A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: Ethical considerations

Ribavirin for patients with Crimean-Congo haemorrhagic fever: A systematic review and meta-analysis

The use of corticosteroid as treatment in SARS was associated with adverse outcomes: A retrospective cohort study

Crimean-Congo hemorrhagic fever: Prognostic factors and the association of leukocyte counts with mortality

Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model

Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice

A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies

Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins

Ebola virus uses clathrin-mediated endocytosis as an entry pathway

Preparation and use of monoclonal antibodies for identifying Crimean-Congo hemorrhagic fever virus

Arbidol inhibits viral entry by interfering with clathrindependent trafficking

Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever

Humanized mouse models to study human diseases. Current Opinion in Endocrinology

Viral agents as biological weapons and agents of bioterrorism

Nosocomial outbreak of viral hemorrhagic fever caused by Crimean Hemorrhagic fever-Congo virus in Pakistan

A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model

Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus

Clinical and laboratory features of Crimean-Congo hemorrhagic fever: Predictors of fatality

Ribavirin is not effective against Crimean-Congo hemorrhagic fever: Observations from the Turkish experience

Fatal outcome of coinfection of Crimean-Congo hemorrhagic fever and malaria

Fundamentals of vaccine immunology

Health care response to CCHF in US soldier and nosocomial transmission to health care providers

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture

Treatment of typhoid fever with convalescent whole blood

Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir

High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever

Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality

Development of vaccines against Crimean-Congo haemorrhagic fever virus

Protective effects of a Modified Vaccinia Ankarabased vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses

Experimental treatment of Ebola virus disease with brincidofovir

Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study

Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: A quasi-experimental study from Turkey

The treatment of Crimean-Congo hemorrhagic fever with high-dose methylprednisolone, intravenous immunoglobulin, and fresh frozen plasma

Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: Severity criteria revisited

Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy

Cytokine response in crimean-congo hemorrhagic fever virus infection

Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-a in patients with Crimean-Congo hemorrhagic fever

Chloroquine interferes with dengue-2 virus replication in U937 cells

Guidance for industry-product development under the animal rule

Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules

Infection prevention and control practice for Crimean-Congo hemorrhagic fever-A multi-center crosssectional survey in Eurasia

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Acute treatment of mania: An update on new medications

A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models

Concerns about the offlicence use of amiodarone for Ebola

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection

High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome

The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia

Crimean-Congo hemorrhagic fever: Case series from a medical center in Golestan province

Crimean-congo hemorrhagic fever: Treatment and control strategy in admitted patients

Development of small-molecule antivirals for Ebola

Sequential determination of serum viral titers, virus-specific IgG antibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patients with Crimean-Congo hemorrhagic fever

Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies

DNA vaccines: Roles against diseases

Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells

Use of humanized mice to study the pathogenesis of autoimmune and inflammatory diseases

The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey

Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. Vector-Borne and Zoonotic Diseases

Certain problems in Crimean hemorrhagic fever therapy

Crimean Hemorrhagic Fever-Materials of the 3rd Scientific-practical Conference in Rostov-na-Donu Region

Haloperidol versus chlorpromazine for treatment of schizophrenia

Clinical implications of antiviral resistance in influenza

Humanized mouse versus non-human primate models of HIV-1 infection

Experimental transmission of Crimean-Congo hemorrhagic fever virus by Hyalomma truncatum Koch

The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran

Dengue viral pathogenesis and immune responses in humanized mice

Lassa fever. Effective therapy with ribavirin

The clinical uses of human serums preserved by the lyophile process

Progression of Ebola therapeutics during the 2014-2015 outbreak

Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine

Fatal nosocomial spread of Crimean-Congo hemorrhagic fever with very short incubation period

Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever

Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality

In vitro inhibition of human influenza A virus replication by chloroquine

Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever. Vector Borne and Zoonotic Diseases

Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: New suggestions

A new immunodeficient hyperglycaemic mouse model based on the Ins2Akita mutation for analyses of human islet and beta stem and progenitor cell function

The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses

Probable Crimean-Congo hemorrhagic fever virus transmission occurred after aerosolgenerating medical procedures in Russia: Nosocomial cluster

Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process

Comparative study between Ribavirin and Ribavirin plus Intravenous Immunoglobulin against Crimean Congo hemorrhagic fever

Effects of chloroquine on viral infections: An old drug against today's diseases?

Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia

Coinfection of malaria and Crimean-Congo hemorrhagic fever

Crimean-Congo hemorrhagic fever

Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice

The mechanism of action of methylprednisolone in the treatment of multiple sclerosis

A comparative study of the Crimean hemorrhagic fever-Congo group of viruses

Pathogenesis of experimental Crimean hemorrhagic fever infection in newborn white mice

Ribavirin for Crimean-Congo hemorrhagic fever: Systematic review and meta-analysis

Crimeancongo hemorrhagic fever in humanized mice reveals glial cells as primary targets of neurological infection

Value of convalescent blood and serum in treatment of influenzal pneumonia

Congo/Crimean haemorrhagic fever in Dubai. An outbreak at the Rashid Hospital

Crimean-Congo haemorrhagic fever and secondary bacteraemia in Turkey

The clinical pathology of Crimean-Congo hemorrhagic fever

Experimental infection of ostriches with Crimean-Congo haemorrhagic fever virus

Mechanisms of action of ribavirin in antiviral therapies

Effects of short-course oral corticosteroid therapy in early dengue infection in vietnamese patients: A randomized, placebo-controlled trial

Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection

A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures

A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part II. Management of patients

Crimean-Congo hemorrhagic fever

Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation

Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin

Crimean-Congo hemorrhagic fever

Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy

Crimean-Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures